Novartis reports positive top-line data from Phase III trial of cardiovascular drug

Novartis has reported positive top-line results from the Phase III CANTOS clinical trial of ACZ885 (canakinumab) and standard-of-care combination to address cardiovascular risk in patients who survived a heart attack.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news